InvestSMART

AVITA Medical, Inc. (ASX: AVH) - Announcements

Current share price for AVH : $1.150 0.01 (0.88%)+

ASX company news and announcements for AVITA Medical, Inc. (AVH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AVITA Medical, Inc. (AVH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AVITA Medical, Inc. (AVH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AVITA Medical, Inc. (AVH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$177 Appendix 4C - quarterly 29 Apr 2013 9:09AM $0.095 $1.150 risen by 1,110.53%
$177 Japanese Patent Granted - Expands Commercial Rights 10 Apr 2013 9:07AM $0.110 $1.150 risen by 945.45%
$177 Half Year Report and Accounts 27 Feb 2013 5:59PM $0.135 $1.150 risen by 751.85%
$177 AVH Completes CE Mark Recertification and ISO Audit 13 Feb 2013 8:25AM $0.140 $1.150 risen by 721.43%
$177 Quarterly Cash Flow Q2 FY13 29 Jan 2013 12:40PM $0.125 $1.150 risen by 820%
$177 Chronic Wound Research underway within key EU Markets 20 Nov 2012 8:27AM $0.120 $1.150 risen by 858.33%
$177 Appendix 4C - quarterly 31 Oct 2012 2:58PM $0.130 $1.150 risen by 784.62%
$177 Avita secures additional funding from US Dept of Defence 28 Sep 2012 9:25AM $0.135 $1.150 risen by 751.85%
$177 Capital Raising 5 Sep 2012 9:55AM $0.130 $1.150 risen by 784.62%
$177 Trading Halt 3 Sep 2012 9:53AM $0.140 $1.150 risen by 721.43%
$177 Preliminary Final Report 31 Aug 2012 10:49AM $0.140 $1.150 risen by 721.43%
$177 June Quarterly Report FY12 31 Jul 2012 12:12PM $0.165 $1.150 risen by 596.97%
$177 Shareholder Update 30 Jul 2012 10:52AM $0.170 $1.150 risen by 576.47%
$177 FDA Study for Cosmetic Indications 10 May 2012 11:22AM $0.225 $1.150 risen by 411.11%
$177 Quarterly Report 27 Apr 2012 10:23AM $0.200 $1.150 risen by 475%
$177 Avita granted EU Patent 5 Apr 2012 10:42AM $0.225 $1.150 risen by 411.11%
$177 Half Yearly Report and Accounts 29 Feb 2012 7:08PM $0.240 $1.150 risen by 379.17%
$177 Successfully completes ISO Quality Recertification 9 Feb 2012 8:23AM $0.130 $1.150 risen by 784.62%
$177 Appendix 4C - quarterly 31 Jan 2012 8:32AM $0.135 $1.150 risen by 751.85%
$177 ReCell Expansion of Sales into Italy 1 Dec 2011 9:25AM $0.105 $1.150 risen by 995.24%
$177 IP Transfer Completed 29 Nov 2011 8:22AM $0.100 $1.150 risen by 1,050%
$177 Appendix 4C - quarterly 28 Oct 2011 3:35PM $0.100 $1.150 risen by 1,050%
$177 Launches ReCell for Treatment of Chronic Ulcers 13 Oct 2011 1:07PM $0.110 $1.150 risen by 945.45%
$177 ReCell JV Middle East and North Africa Launch 7 Sep 2011 9:46AM $0.110 $1.150 risen by 945.45%
$177 Preliminary Final Report 31 Aug 2011 9:49AM $0.095 $1.150 risen by 1,110.53%

1276 - 1300 of 1352 results

Page 52 of 55

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.